Shilpa Medicare Share Price in Focus; Subsidiary Signs Licensing Deal with SteinCares for Latin America

Shilpa Medicare Limited announced on February 24, 2026, that its subsidiary, Shilpa Biologicals Pvt Ltd, has signed a licensing agreement with SteinCares, Costa Rica, to expand biosimilar access in Latin America. 

Licensing Agreement Details 

Under the agreement, SteinCares will hold exclusive rights to register, commercialise, and distribute the biosimilar across Latin America. Shilpa Biologicals will complete product development and provide long term commercial manufacturing from its facility in Dharwad, India. The collaboration aims to leverage SteinCares' regional platform and Shilpa's biologics expertise. 

Partnership Objectives 

The partnership focuses on expanding patient access to cost effective biosimilars in Latin America. SteinCares brings regulatory and market access capabilities, while Shilpa Biologicals contributes development and manufacturing expertise. This marks Shilpa Biologicals' first entry into the Latin American market. 

Company Profiles 

SteinCares operates in 30 Latin American and Caribbean countries, specialising in biosimilars and complex generics. Shilpa Biologicals, a subsidiary of Shilpa Medicare, is an integrated biopharmaceutical company with a pipeline of biosimilars in immunology, oncology, and ophthalmics. 

Read More: Zydus Launches India’s First Indigenous Aflibercept Biosimilar ANYRA™ for Eye Care! 

Shilpa Medicare Share Price Performance  

As of February 24, 2026, at 1:29 PM, Shilpa Medicare share price on NSE was trading at ₹321.40 down by 1.64% from the previous closing price. 

Conclusion 

The licensing agreement between Shilpa Biologicals and SteinCares aims to enhance biosimilar accessibility in Latin America. The collaboration combines Shilpa's manufacturing capabilities with SteinCares' regional commercialisation network. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.